MOLINA HEALTHCARE INC
For the period ended Dec 31, 2024. Filed Feb 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 11, 2025
MOH$209.49-0.2%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Checking your notes…
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| (In millions) | |||
| Operating activities: | |||
| Net income | $1,179 | $1,091 | $792 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 186 | 171 | 176 |
| Deferred income taxes | 53 | (31) | (66) |
| Share-based compensation | 116 | 115 | 103 |
| Impairment | — | — | 208 |
| Other, net | 8 | 2 | 8 |
| Changes in operating assets and liabilities, net of the effect of acquisitions: | |||
| Receivables | (78) | (778) | (95) |
| Prepaid expenses and other current assets | (57) | (69) | (124) |
| Medical claims and benefits payable | (40) | 580 | 153 |
| Amounts due government agencies | (453) | 196 | (428) |
| Accounts payable, accrued liabilities and other | 115 | 328 | 55 |
| Deferred revenue | (367) | 59 | (11) |
| Income taxes | (18) | (2) | 2 |
| Net cash provided by operating activities | 644 | 1,662 | 773 |
| Investing activities: | |||
| Purchases of investments | (1,132) | (1,433) | (1,913) |
| Proceeds from sales and maturities of investments | 1,111 | 772 | 1,398 |
| Net cash paid in business combinations | (344) | (3) | (134) |
| Purchases of property, equipment and capitalized software | (100) | (84) | (91) |
| Other, net | 1 | 4 | (50) |
| Net cash used in investing activities | (464) | (744) | (790) |
| Financing activities: | |||
| Common stock purchases | (1,000) | — | (400) |
| Proceeds from senior notes offerings, net of issuance costs | 740 | — | — |
| Proceeds from borrowings under credit facility | 300 | — | — |
| Repayment of credit facility | (300) | — | — |
| Common stock withheld to settle employee tax obligations | (57) | (60) | (54) |
| Contingent consideration liabilities settled | — | — | (20) |
| Other, net | (30) | 2 | 33 |
| Net cash used in financing activities | (347) | (58) | (441) |
| Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents | (167) | 860 | (458) |
| Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period | 4,908 | 4,048 | 4,506 |
| Cash and cash equivalents, and restricted cash and cash equivalents at end of period | $4,741 | $4,908 | $4,048 |
(continued)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| (In millions) | |||
| Supplemental cash flow information: | |||
| Cash paid during the period for: | |||
| Income taxes, net | $379 | $405 | $340 |
| Interest | $121 | $108 | $108 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.